Positionspapier der Kommission Digitale Rheumatologie der Deutschen Gesellschaft für Rheumatologie e. V.: Aufgaben, Ziele und Perspektiven für eine moderne Rheumatologie

Knitza, Johannes; Callhoff, Johanna; Chehab, Gamal; Hueber, Axel J.; Kiltz, Uta; Kleyer, Arnd; Krusche, Martin; Simón, David; Specker, Christof; Schneider, Matthias; Voormann, Anna; Welcker, Martin

doi:10.1007/s00393-020-00834-y

Cited by 18 publications

(6 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Apps und Wearables für medizinische Zwecke sind aktuell (auch aufgrund der DiGAV) ein neues und viel umworbenes Feld, das von verschiedenen Akteuren genutzt wird [33]. Die Einsatzmöglichkeiten dieser Technologien z.…”

Section: Apps Und Wearablesunclassified

Telemedizin in der Rheumatologie

Krusche

Muehlensiepen

Aries³

et al. 2020

Z Rheumatol

Self Cite

View full text Add to dashboard Cite

Zusammenfassung Der Ausbruch der COVID-19-Pandemie geht mit tief greifenden Einschnitten im Alltag und im Berufsleben einher – sowohl gesamtgesellschaftlich als auch speziell im Gesundheitswesen. Im Fokus der Pandemieeindämmung haben sich vielerorts rheumatologische Routineabläufe verändert. Um den entsprechenden Infektionsschutz der Patienten und des medizinischen Personals gewährleisten zu können, wurde hier verstärkt Telemedizin (insbesondere Telefon- und Videosprechstunde) eingesetzt. Weiterhin stehen durch die Digitale-Gesundheitsanwendungen-Verordnung (DiGAV) voraussichtlich in den kommenden Monaten neue, abrechnungsfähige telemedizinische Anwendungsmöglichkeiten wie Apps und Wearables zur Verfügung. Der Artikel soll einen Überblick über telemedizinische Versorgungsmöglichkeiten in der Rheumatologie (mit besonderem Fokus auf die Videosprechstunde) geben. Weiterhin wird Bezug auf die vorhandene Evidenzlage sowie Chancen und Limitation der Telemedizin im Fachgebiet genommen.

show abstract

Section: Apps Und Wearablesunclassified

Telemedizin in der Rheumatologie

Krusche

Muehlensiepen

Aries³

et al. 2020

Z Rheumatol

Self Cite

View full text Add to dashboard Cite

show abstract

“…The Mida Rheuma App provides a personalized series of treatment action plans in the areas of dietary, mental health, lifestyle factors and physical activity, based on information and preferences that is tracked via a chatbot. The Mida Rheuma App was developed in accordance with recent EULAR guideline recommendations [ 21 , 30 , 31 ] and in close cooperation with patients and doctors. This continuous feedback-loop enables predictive, preventive, personalized and participatory (“P4”) medicine [ 32 ].…”

Section: Introductionmentioning

confidence: 99%

Efficacy and safety of a mobile app intervention in patients with inflammatory arthritis: a prospective pilot study

et al. 2022

View full text Add to dashboard Cite

EULAR highlighted the essential role of digital health in increasing self-management and improving clinical outcomes in patients with arthritis. The objective of this study was to evaluate the efficacy and safety of the digital health application (DHA) in patients with inflammatory arthritis. We assessed demographic parameters, treatment regimen, disease activity, and other patient-reported outcomes at baseline and after 4 weeks of DHA use added to standard care treatment. Of 17 patients, who completed the study, 7 (41.2%) patients were male, ranging from 19 to 63 (40.5 ± 12.2) years. No significant change in antirheumatic treatment was observed during the study. Statistically significant improvements (p < 0.05) were noted for health-related quality of life (increase in Physical Component Summary of Short Form-36 (SF-36) by 23.6%) and disease activity (decrease of Clinical Disease Activity Index and Simple Disease Activity Index by 38.4% and 39.9%, respectively). Clinically significant improvement was demonstrated for SF-36 Total Score (+ 14.4%), disease activity (Rheumatoid Arthritis Disease Activity Index− 5 to 15.9%), and depression (Patient Health Questionnaire− 9 to 13.5%). None of the efficacy parameters showed negative trends. No adverse events were reported throughout the study. The usability level was high i.e., the mean mHealth Application Usability Questionnaire Score of 5.96 (max.: 7.0) demonstrated a high level of application usability. This suggests that using a personalized disease management program based on DHA significantly improves several measures of patient-reported outcomes and disease activity in patients with inflammatory arthritis in a timely manner. These findings highlight the potential of complementary digital therapy in patients with inflammatory arthritis.

show abstract

“…(e.g. [ 8 – 10 ]). In this article, we analyze an often neglected issue: the potential disruption of the management of care in rheumatology: who—person or software—takes care of the patient?…”

Section: Introductionmentioning

confidence: 99%

Digitalization and disruptive change in rheumatology

Richter

Lieb²,

Steimann

et al. 2022

Z Rheumatol

View full text Add to dashboard Cite

Introduction Recently, many sectors have seen disruptive changes due to the rapid progress in information and communication technology (ICT). The aim of this systematic literature review was to develop a first understanding of what is known about new ICTs in rheumatology and their disruptive potential. Methods PubMed, LIVIVO, and EBSCO Discovery Service (EDS) databases were searched for relevant literature. Use of new ICTs was identified, categorized, and disruptive potential was discussed. Articles from 2008 to 2021 in German and English were considered. Results A total of 3539 articles were identified. After application of inclusion/exclusion criteria, 55 articles were included in the analyses. The majority of articles (48) used a non-experimental design or detailed expert opinion. The new ICTs mentioned in these articles could be allocated to four main categories: technologies that prepare for the development of new knowledge by data collection (n = 32); technologies that develop new knowledge by evaluation of data (e.g., by inventing better treatment; n = 11); technologies that improve communication of existing knowledge (n = 32); and technologies that improve the care process (n = 29). Further assessment classified the ICTs into different functional subcategories. Based on these categories it is possible to estimate the disruptive potential of new ICTs. Conclusion ICTs are becoming increasingly important in rheumatology and may impact patients’ lives and professional conduct. The properties and disruptive potential of technologies identified in the articles differ widely. When looking into ICTs, doctors have focused on new diagnostic and therapeutic procedures but rarely on their disruptive potential. We recommend putting more effort into investigation of whether ICTs change the way rheumatology is performed and who is in control of it. Especially technologies that potentially replace physicians with machines, take control over the definition of quality in medicine, and/or create proprietary knowledge that is not accessible for doctors need more research.

show abstract

Positionspapier der Kommission Digitale Rheumatologie der Deutschen Gesellschaft für Rheumatologie e. V.: Aufgaben, Ziele und Perspektiven für eine moderne Rheumatologie

Cited by 18 publications

References 29 publications

Telemedizin in der Rheumatologie

Telemedizin in der Rheumatologie

Efficacy and safety of a mobile app intervention in patients with inflammatory arthritis: a prospective pilot study

Digitalization and disruptive change in rheumatology

Contact Info

Product

Resources

About